GSK

London, UK, 23-10-2013 — /EuropaWire/ — GSK announces Q3 core EPS growth of 16% and dividend of 19p Core EPS 28.9p (+16%) benefiting from operating, financial and long-term cost efficiencies Pharma & Vaccines sales flat: US +2%, Europe +5%, Japan +2% offset by … Read the full press release →

London, UK, 23-10-2013 — /EuropaWire/ — GlaxoSmithKline plc (LSE:GSK) today announced the submission of a New Drug Application (NDA) in the US for the once daily inhaled corticosteroid (ICS) treatment, fluticasone furoate (FF), administered using the ELLIPTA™ dry powder inhaler. The NDA … Read the full press release →

London, UK, 23-10-2013 — /EuropaWire/ — ViiV Healthcare today announced the submission of a regulatory application in the United States for its investigational single-tablet regimen (STR) combining dolutegravir, abacavir and lamivudine for the treatment of people living with HIV-1. This New Drug … Read the full press release →

Continued improvement in financial performance Cash and short-term investments of CHF 262.8 million Guidance on isavuconazole phase 3 topline data and ceftobiprole regulatory decision in Europe maintained for H2 2013 Significant agreement with BARDA of up to USD 89 million … Read the full press release →

22-7-2013 — /EuropaWire/ — Following a meeting with the Chinese Ministry of Public Security to discuss their investigation into GSK, Abbas Hussain, President International – Europe, Japan, Emerging Markets & Asia Pacific said: “We have had a very constructive meeting with the … Read the full press release →